Richard E. Cutler

3.1k citations

46 papers · 1.6k indexed · 1 hit paper · h-index 19

Impact in

Oncology top 5%
- HER2/EGFR in Cancer Research
Molecular Biology top 10%
- Protein Kinase Regulation and GTPase Signaling
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- 14-3-3 protein interactions
- Cell death mechanisms and regulation

Papers in

Oncology 20
- HER2/EGFR in Cancer Research 15
Genetics 7
- Estrogen and related hormone effects 6
- Chronic Lymphocytic Leukemia Research 4

Co-authors: Deborah K. Morrison Robert M. Stephens Misty Saracino Mary Hunzicker-Dunn Alshad S. Lalani Evelyn T. Maizels Carl A. Peters Jane L. Roberts
Journals: Cancer Research (8 papers)Cancer Biology & Therapy (4 papers)Clinical Cancer Research (3 papers)Biochemical Journal (3 papers)Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2 papers)
Partner nations: United States Spain France

In The Last Decade

Richard E. Cutler

44 papers receiving 1.6k citations

Hit Papers

align trajectories log scale

The complexity of Raf-1 regulation 1997 · 525 citations

Peers

Countries citing papers authored by Richard E. Cutler

Since Specialization

Citations

This map shows the geographic impact of Richard E. Cutler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard E. Cutler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard E. Cutler more than expected).

Fields of papers citing papers by Richard E. Cutler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard E. Cutler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard E. Cutler. The network helps show where Richard E. Cutler may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Richard E. Cutler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Richard E. Cutler Line = papers co-authored together Richard E. Cutler links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma Cancer Research Communications ·Glenn J. Hanna, Gregory M. Coté, Rashmi Chugh, Jacob Thomas, Jyoti Malhotra, Richard E. Cutler, Tressa Hood, W. Busch, Elizabeth Olek, Miguel A. Villalona‐Calero	2025	0
2	Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors Cancer Research ·Monica Mita, Alain C. Mita, Miguel A. Villalona‐Calero, Noah Federman, Drew Rasco, David R. Spigel, Jia Luo, Gregory M. Coté, Richard E. Cutler, Pavan Kumar, Crystal MacKenzie, Charles Y. Lin, Jorge DiMartino, Elizabeth Olek, Brian A. Van Tine	2024	1
3	Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors. Journal of Clinical Oncology ·Miguel A. Villalona‐Calero, Glenn J. Hanna, Mark Agulnik, Monica Mita, Alain C. Mita, David R. Spigel, Jia Luo, Gregory M. Coté, Jyoti Malhotra, Mohamad A. Salkeni, Natraj Reddy Ammakkanavar, Z. A. Zhu, Kamalesh K. Sankhala, Richard E. Cutler, Tressa Hood, Luis A. Carvajal, Charles Y. Lin, Jorge DiMartino, Elizabeth Olek, Brian A. Van Tine	2024	7
4	Abstract B112: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed, refractory ovarian cancer and transcriptionally addicted relapsed or refractory solid tumors Cancer Research ·Miguel A. Villalona‐Calero, Monica Mita, Alain C. Mita, Noah Federman, Drew Rasco, David R. Spigel, Jia Luo, Gregory M. Coté, Richard E. Cutler, Pavan Kumar, Li Ying-Jin, Charles Y. Lin, Jorge DiMartino, Elizabeth Olek, Brian A. Van Tine	2024	1
5	PB1889: KB-LANRA 1001: A PHASE 1B/2 STUDY ON SAFETY, PK, PD, AND PRELIMINARY EFFICACY OF THE SELECTIVE SYK INHIBITOR LANRAPLENIB IN COMBINATION WITH THE FLT3 INHIBITOR GILTERITINIB, IN FLT3-MUTATED R/R AML HemaSphere ·Anand Patel, Laura C. Michaelis, Gary J. Schiller, Ronan Swords, Lawrence E. Morris, Luis A. Carvajal, Gordon L. Bray, Elizabeth Olek, Richard E. Cutler, Jorge DiMartino, Eytan M. Stein	2023	1
6	Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer Annals of Oncology ·Lillian M. Smyth, Cristina Saura, Sarina A. Piha‐Paul, Janice Lu, Ingrid A. Mayer, Carl Aberle, Iben Spanggaard, Mónica Arnedos, Richard E. Cutler, David M. Hyman	2019	15
7	Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer Breast Cancer Research ·Ricardo Ribas, Sunil Pancholi, Aradhana Rani, Eugene F. Schuster, Stephanie K. Guest, Joanna Nikitorowicz-Buniak, Nikiana Simigdala, James Ricau, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Mitch Dowsett, Stephen Johnston, Lesley‐Ann Martin	2018	16
8	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial Clinical Cancer Research ·Dhivya R. Sudhan, Luis J. Schwarz, Ángel Guerrero‐Zotano, Luigi Formisano, Mellissa J. Nixon, Sarah Croessmann, Paula I. González-Ericsson, Melinda E. Sanders, Justin M. Balko, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan Auerbach, Carlos L. Arteaga	2018	26
9	Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer Clinical Cancer Research ·Sarah Croessmann, Luigi Formisano, Lisa N. Kinch, Paula I. González-Ericsson, Dhivya R. Sudhan, Rebecca J. Nagy, Aju Mathew, Eric Bernicker, Massimo Cristofanilli, Jie He, Richard E. Cutler, Alshad S. Lalani, Vincent A. Miller, Richard B. Lanman, Nick V. Grishin, Carlos L. Arteaga	2018	78
10	The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells Cancer Biology & Therapy ·Laurence Booth, Jane L. Roberts, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Andrew Poklepovic, Paul Dent	2018	8
11	Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations Breast Cancer Research and Treatment ·Lynn Jongen, Giuseppe Floris, Bram Boeckx, Dominiek Smeets, Diether Lambrechts, Sara Vander Borght, Annouschka Laenen, Grace Mann, Richard E. Cutler, Alshad S. Lalani, Patrick Neven, Hans Wildiers	2018	2
12	An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer Cancer Discovery ·Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory Sliwoski, Rebecca J. Nagy, Richard B. Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent A. Miller, Richard E. Cutler, Alshad S. Lalani, Darren A.E. Cross, Christine M. Lovly, Jens Meiler, Carlos L. Arteaga	2017	75
13	[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration Oncotarget ·Laurence Booth, Jane L. Roberts, H Lewis, John M. Kirkwood, Francesca Avogadri-Connors, Richard E. Cutler, Alshad S. Lalani, Andrew Poklepovic, Paul Dent	2017	23
14	EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation Clinical Cancer Research ·Torsten Trowe, Sotiria Boukouvala, Iman AL-GHAFRI, Richard E. Cutler, Yutaro Yiwamoto, Roel Funke, Steven Gendreau, 正紀梅原, Nicole Miller, John Woolfrey, Valentina Vysotskaia, A. Jaya Mabel Rani, Mary E. Gerritsen, David J. Matthews, Peter Lamb, Timothy S. Heuer	2008	94
15	Stk10, a New Member of the Polo-like Kinase Kinase Family Highly Expressed in Hematopoietic Tissue Journal of Biological Chemistry ·Callon, Richard E. Cutler, Carlos Andrés Ulloa Vaca, Mikhail L. Gishizky, Ronald J. Hill	2003	47
16	Regulation of PKC δ expression by estrogen and rat placental lactogen-1 in luteinized rat ovarian granulosa cells Molecular and Cellular Endocrinology ·Carl A. Peters, Richard E. Cutler, Evelyn T. Maizels, May C. Robertson, Robert P. C. Shiu, Phillip A. Fields, Mary Hunzicker-Dunn	2000	13
17	Regulation of protein kinase C δ by estrogen in the MCF-7 human breast cancer cell line Molecular and Cellular Endocrinology ·Ecole nationale d'économie appliquée, Nancy Krett, Evelyn T. Maizels, Richard E. Cutler, Carl A. Peters, Leia M. Smith, Michelle L. O’Brien, Ok-Kyong Park-Sarge, Steven T. Rosen, Mary Hunzicker-Dunn	1999	44
18	Identification of Residues in the Cysteine-rich Domain of Raf-1 That Control Ras Binding and Raf-1 Activity Journal of Biological Chemistry ·David G. Winkler, Richard E. Cutler, Jonelle K. Drugan, Sharon L. Campbell, Deborah K. Morrison, Jonathan A. Cooper	1998	38
19	Autoregulation of the Raf-1 serine/threonine kinase Proceedings of the National Academy of Sciences ·Richard E. Cutler, Robert M. Stephens, Misty Saracino, Deborah K. Morrison	1998	151
20	Calcium-independent phospholipid / diolein-dependent phosphorylation of a soluble ovarian Mr 80 000 substrate protein: Biochemical characteristics Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Evelyn T. Maizels, Josephine B. Miller, Richard E. Cutler, Victoria Jackiw, SB Chandra, Pham Duy Trong, Mary Hunzicker-Dunn	1990	14

About Richard E. Cutler

Richard E. Cutler is a scholar working on Oncology, Genetics, Pulmonary and Respiratory Medicine, Reproductive Medicine and Physiology, having authored 46 papers that have together received 1.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (17 papers), HER2/EGFR in Cancer Research (15 papers), Lung Cancer Treatments and Mutations (7 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Estrogen and related hormone effects (6 papers), Protein Kinase Regulation and GTPase Signaling (5 papers), Ubiquitin and proteasome pathways (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). The work is most often cited by research in Oncology (506 citations), Molecular Biology (1.1k citations), Cell Biology (234 citations), Cancer Research (165 citations) and Genetics (112 citations). Richard E. Cutler has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Deborah K. Morrison, Robert M. Stephens, Misty Saracino, Mary Hunzicker-Dunn, Alshad S. Lalani, Evelyn T. Maizels, Carl A. Peters, Jane L. Roberts, Paul Dent and Francesca Avogadri-Connors. Their work appears in journals such as Cancer Research, Cancer Biology & Therapy, Clinical Cancer Research, Biochemical Journal and Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact